Heron Therapeutics Inc vs QUALCOMM, Inc. — how do they compare? Heron Therapeutics Inc trades at $0.48 (market cap $91.46M), while QUALCOMM, Inc. trades at $172.09 (market cap $179.52B). The key difference: QUALCOMM, Inc. is far larger — about 1962.8× Heron Therapeutics Inc's market cap, and QUALCOMM, Inc. pays a 2.16% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | QCOM | |
|---|---|---|
Market Cap | $91.46M | $179.52B |
Sector | Health | Technology |
52-Week High | $1.96 | $251.10 |
52-Week Low | $0.39 | $124.07 |
Enterprise Value | $189.36M | $184.99B |
Dividend Yield | — | 2.16% |
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
Qualcomm (QCOM) trades at $171.78, up 0.64% with a bearish technical signal despite recent earnings beats. The company shows strong profitability with 54.8% gross margins and 22.31% net income margins, though revenue growth remains modest. Recent news highlights Qualcomm's AI and data center expansion efforts while facing smartphone market headwinds and increased competition from Nvidia's PC chip entry.
The stock presents a mixed outlook with attractive valuation (P/E 18.31) and analyst consensus target of $228.22 offering 33% upside potential. However, margin pressures and competitive threats from Nvidia's market expansion create near-term uncertainty. Institutional sentiment leans neutral with 50% hold ratings, suggesting cautious optimism about Qualcomm's diversification strategy.
Trailing returns across standard periods
Latest headlines on both assets
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →